Aardvark Therapeutics, Inc. (AARD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Aardvark Therapeutics reported revenue of $0. Net income was -$57.6M, or -$2.93 per diluted share. Operating activities generated -$54.2M of cash, leaving -$54.3M of free cash flow. At fiscal year end, Aardvark Therapeutics held $117.2M in total assets against $10.5M in total liabilities, including $47.1M of cash and equivalents.
Open the full interactive Aardvark Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Aardvark Therapeutics Key Stats
| Share Price | $4.04 |
|---|---|
| Market Cap | $88.3M |
| 52-Week Range | $3.48 – $15.82 |
| Shares Outstanding | 21.8 million (basic, 2026 Q2) |
Aardvark Therapeutics Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$62.7M |
| Pre-Tax Income | -$57.6M |
| Income Tax | $0 |
| Net Income | -$57.6M |
| Diluted EPS | -$2.93 |
Aardvark Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.4M | — | $0 | $695,000 |
| Net Income | -$16.3M | -$17.6M | -$21.6M | -$14.4M |
| Diluted EPS | -$0.75 | -$0.90 | -$0.99 | -$0.66 |
Aardvark Therapeutics Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $47.1M |
| Current Assets | $111.9M |
| Total Assets | $117.2M |
| Current Liabilities | $10.5M |
| Total Liabilities | $10.5M |
| Shareholders' Equity | $106.6M |
Aardvark Therapeutics Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$54.2M |
| Cash From Investing | -$49.7M |
| Cash From Financing | $89.2M |
| Free Cash Flow | -$54.3M |
Figures from Aardvark Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aardvark Therapeutics financials page for every line item.
Aardvark Therapeutics Company Profile
| Ticker | AARD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001774857 |
Frequently Asked Questions
What was Aardvark Therapeutics' revenue in fiscal 2025?
Aardvark Therapeutics (AARD) reported revenue of $0 for fiscal 2025.
What was Aardvark Therapeutics' net income in fiscal 2025?
Aardvark Therapeutics reported net income of -$57.6M for fiscal 2025.
What was Aardvark Therapeutics' earnings per share (EPS) in fiscal 2025?
Aardvark Therapeutics' diluted EPS was -$2.93 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Aardvark Therapeutics generate in fiscal 2025?
Aardvark Therapeutics generated -$54.3M of free cash flow in fiscal 2025.
What was Aardvark Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Aardvark Therapeutics reported revenue of $695,000.
How many shares of Aardvark Therapeutics are outstanding?
Aardvark Therapeutics reported a weighted average of 21.8 million basic shares outstanding in 2026 Q2.
What is Aardvark Therapeutics' market cap?
Based on its latest closing price, Aardvark Therapeutics (AARD) has a market capitalization of about $88.3M.
When does Aardvark Therapeutics' fiscal year end?
Aardvark Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Aardvark Therapeutics headquartered?
Aardvark Therapeutics lists its business address in San Diego, California in its SEC filings.